153 related articles for article (PubMed ID: 19260467)
1. Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma.
Xu H; Inagaki Y; Tang W; Guo Q; Wang F; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Hepatogastroenterology; 2008; 55(88):2000-4. PubMed ID: 19260467
[TBL] [Abstract][Full Text] [Related]
2. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308
[TBL] [Abstract][Full Text] [Related]
3. Expression of KL-6 mucin, a human MUC1 mucin, in intrahepatic cholangiocarcinoma and its potential involvement in tumor cell adhesion and invasion.
Xu HL; Inagaki Y; Seyama Y; Sugawara Y; Kokudo N; Nakata M; Wang FS; Tang W
Life Sci; 2009 Aug; 85(9-10):395-400. PubMed ID: 19631667
[TBL] [Abstract][Full Text] [Related]
4. KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma.
Zhang K; Tang W; Qu X; Guo Q; Inagaki Y; Seyama Y; Abe H; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
Hepatogastroenterology; 2009; 56(93):960-3. PubMed ID: 19760920
[TBL] [Abstract][Full Text] [Related]
5. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases.
Satoh H; Kurishima K; Ishikawa H; Ohtsuka M
J Intern Med; 2006 Nov; 260(5):429-34. PubMed ID: 17040248
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of the serum KL-6 assay in patients with hepatitis C virus.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2005; 48(6):400-4. PubMed ID: 16024944
[TBL] [Abstract][Full Text] [Related]
10. Significance of the serum level of soluble E-cadherin in patients with HCC.
Soyama A; Eguchi S; Takatsuki M; Kawashita Y; Hidaka M; Tokai H; Nagayoshi S; Mochizuki S; Matsumoto S; Hamasaki K; Tajima Y; Kanematsu T
Hepatogastroenterology; 2008; 55(85):1390-3. PubMed ID: 18795696
[TBL] [Abstract][Full Text] [Related]
11. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma.
Scholz A; Rehm VA; Rieke S; Derkow K; Schulz P; Neumann K; Koch I; Pascu M; Wiedenmann B; Berg T; Schott E
Am J Gastroenterol; 2007 Nov; 102(11):2471-81. PubMed ID: 17581268
[TBL] [Abstract][Full Text] [Related]
12. Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome.
Nakashima T; Yokoyama A; Ohnishi H; Hamada H; Ishikawa N; Haruta Y; Hattori N; Tanigawa K; Kohno N
J Intern Med; 2008 Apr; 263(4):432-9. PubMed ID: 18298483
[TBL] [Abstract][Full Text] [Related]
13. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis.
Yokoyama A; Kondo K; Nakajima M; Matsushima T; Takahashi T; Nishimura M; Bando M; Sugiyama Y; Totani Y; Ishizaki T; Ichiyasu H; Suga M; Hamada H; Kohno N
Respirology; 2006 Mar; 11(2):164-8. PubMed ID: 16548901
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers.
Inagaki Y; Xu H; Nakata M; Seyama Y; Hasegawa K; Sugawara Y; Tang W; Kokudo N
Biosci Trends; 2009 Dec; 3(6):220-32. PubMed ID: 20103851
[TBL] [Abstract][Full Text] [Related]
16. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma.
Tamesa T; Iizuka N; Mori N; Okada T; Takemoto N; Tangoku A; Oka M
Hepatogastroenterology; 2009; 56(93):1122-6. PubMed ID: 19760954
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma.
Massironi S; Fraquelli M; Paggi S; Sangiovanni A; Conte D; Sciola V; Ciafardini C; Colombo M; Peracchi M
Dig Liver Dis; 2009 Jan; 41(1):31-5. PubMed ID: 18762462
[TBL] [Abstract][Full Text] [Related]
18. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma.
Cheng KS; Tang HL; Chou FT; Chou JW; Hsu CH; Yu CJ; Kao ST; Li TC
Hepatogastroenterology; 2009; 56(93):1105-10. PubMed ID: 19760951
[TBL] [Abstract][Full Text] [Related]
19. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
[TBL] [Abstract][Full Text] [Related]
20. [Establishment of reference intervals and cut-off value by an enzyme immunoassay for KL-6 antigen, a new marker for interstitial pneumonia].
Kobayashi J; Itoh Y; Kitamura S; Kawai T
Rinsho Byori; 1996 Jul; 44(7):653-8. PubMed ID: 8801361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
